MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
48.09
+1.62
+3.49%
After Hours: 46.33 -1.76 -3.66% 19:44 03/14 EDT
OPEN
46.84
PREV CLOSE
46.47
HIGH
48.23
LOW
45.60
VOLUME
487.72K
TURNOVER
--
52 WEEK HIGH
57.28
52 WEEK LOW
20.08
MARKET CAP
1.85B
P/E (TTM)
-15.6497
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-Tarsus Pharma dips after upsized $125 mln stock offering
Reuters · 2d ago
Tarsus prices $125M stock offering
Seeking Alpha · 2d ago
*Tarsus Pharmaceuticals Specializes in Developing Treatments for Eye-Care Diseases >TARS
Dow Jones · 2d ago
*Tarsus: Goldman Sachs, BofA Securities Among Managers for Offering >TARS
Dow Jones · 2d ago
*Tarsus Expects Gross Proceeds of About $125.0M From Offering >TARS
Dow Jones · 2d ago
*Tarsus Expects Offering to Close March 14 >TARS
Dow Jones · 2d ago
*Tarsus Underwriters Have Option to Purchase Up to 421,348 Additional Shares >TARS
Dow Jones · 2d ago
*Tarsus Prices Upsized Public Offering of 2.8M Shares at $44.50 Each >TARS
Dow Jones · 2d ago
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.